We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $875B
1-Year Est. Return 40.91%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALLK
11601
PUT
DELISTED
Allakos
ALLK
$70K ﹤0.01%
22,500
-17,300
-43% -$64.6K
BCLI
11602
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$70K ﹤0.01%
1,712
+104
+6% +$4.68K
CISO
11603
CALL
CISO Global
CISO
$12.2M
$70K ﹤0.01%
1,293
-787
-38% -$61.1K
DOGZ icon
11604
CALL
Dogness International Corp
DOGZ
$16.8M
$70K ﹤0.01%
1,920
-1,820
-49% -$145K
FBRX icon
11605
CALL
Forte Biosciences
FBRX
$1.63B
$70K ﹤0.01%
2,160
+1,236
+134% +$39.3K
LPCN icon
11606
CALL
Lipocine
LPCN
$17.4M
$70K ﹤0.01%
5,124
+465
+10% +$7.25K
LUCD icon
11607
Lucid Diagnostics
LUCD
$197M
$70K ﹤0.01%
30,827
+10,332
+50% +$23K
OPTN
11608
DELISTED
OptiNose
OPTN
$70K ﹤0.01%
1,284
-451
-26% -$16.6K
FNCH
11609
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$70K ﹤0.01%
826
-1,165
-59% -$99.6K
OTIC
11610
CALL
DELISTED
Otonomy, Inc.
OTIC
$70K ﹤0.01%
33,700
-36,900
-52% -$76.8K
USWS
11611
DELISTED
U.S. Well Services, Inc. Class A Common Stock
USWS
$70K ﹤0.01%
+12,437
New +$62.4K
ELTX icon
11612
Elicio Therapeutics
ELTX
$81.2M
$69K ﹤0.01%
+6,016
New +$96.1K
IGC icon
11613
IGC Pharma
IGC
$31.1M
$69K ﹤0.01%
129,190
+119,183
+1,191% +$75.2K
IREN icon
11614
Iris Energy
IREN
$15.7B
$69K ﹤0.01%
+20,494
New +$159K
LFMD icon
11615
CALL
LifeMD
LFMD
$166M
$69K ﹤0.01%
33,700
-15,400
-31% -$38.3K
MKTW icon
11616
CALL
MarketWise
MKTW
$54.2M
$69K ﹤0.01%
955
+365
+62% +$25.4K
NINE
11617
PUT
DELISTED
Nine Energy Service
NINE
$69K ﹤0.01%
26,000
-8,800
-25% -$26.5K
SACH
11618
Sachem Capital Corp
SACH
$37.9M
$69K ﹤0.01%
+16,953
New +$79.7K
SES icon
11619
PUT
SES AI
SES
$223M
$69K ﹤0.01%
17,500
-18,900
-52% -$121K
TANH icon
11620
Tantech Holdings
TANH
$5.73M
$69K ﹤0.01%
+246
New +$81.4K
ACHL
11621
DELISTED
Achilles Therapeutics
ACHL
$69K ﹤0.01%
27,468
+9,456
+52% +$23.3K
KA
11622
PUT
DELISTED
Kineta, Inc. Common Stock
KA
$69K ﹤0.01%
5,414
+3,171
+141% +$30.4K
CHS
11623
PUT
DELISTED
Chicos FAS, Inc.
CHS
$69K ﹤0.01%
13,900
-10,700
-43% -$54.1K
ACER
11624
CALL
DELISTED
Acer Therapeutics Inc
ACER
$69K ﹤0.01%
+54,500
New +$114K
SBIG
11625
DELISTED
SpringBig Holdings, Inc. Common Stock
SBIG
$69K ﹤0.01%
+38,728
New +$104K

Similar funds

Citadel Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Citadel Advisors held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Citadel Advisors's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Citadel Advisors's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Citadel Advisors added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Citadel Advisors's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Citadel Advisors fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Citadel Advisors's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Citadel Advisors opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Citadel Advisors's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.